Drug intelligence / Profile preview

IMG-017

Development stage: Preclinical
Lead developer: Maijin Biomedical Technology
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

IMG-017 is a monoclonal antibody drug candidate developed by Maijin Biomedical Technology (Shanghai) Co., Ltd. It targets BDCA2 (C-Type lectin domain family 4 member C), acting as an inhibitor of this receptor. BDCA2 is primarily expressed on plasmacytoid dendritic cells and plays a role in modulating immune responses, making it a potential target for autoimmune or inflammatory diseases. As of March 2025, IMG-017 remains in preclinical development, with no reported clinical trial phases or approved indications[8].

Targets

CLEC4C (C-type lectin domain family 4 member C)

Beyond the preview

Go deeper on IMG-017.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IMG-017.

Explore the full profile